Patient characteristics, N = 201
Characteristic . | n (%) . |
---|---|
Underlying disease | |
Lymphoma | 12 (6.0) |
Acute leukemia | 59 (29.4) |
Chronic leukemia | 95 (47.3) |
Aplastic anemia | 11 (5.5) |
Myelodysplastic syndrome | 19 (9.5) |
Miscellaneous | 5 (2.5) |
Source of stem cells | |
Bone marrow | 169 (84.1) |
Peripheral mobilized stem cell | 32 (15.9) |
Age, y; median (range) | 40 (2-66) |
Sex | |
Male | 116 (57.7) |
Female | 85 (42.3) |
Transplant type | |
Matched related | 133 (66.2) |
Mismatched/unrelated | 68 (33.8) |
Total body irradiation conditioning | 105 (52.2) |
Received ganciclovir | |
Yes | 154 (76.6) |
No | 46 (22.9) |
Data not available | 1 (0.5) |
Steroid use* | |
None | 77 (39.1) |
Between 0 and 1 mg/kg/d | 62 (31.5) |
At least 2 mg/kg/d | 58 (29.4) |
GVHD | |
Grade 0 to 1 | 62 (30.9) |
Grade II | 103 (51.2) |
At least grade III | 36 (17.9) |
Donor CMV serology | |
Positive | 131 (65.2) |
Negative | 70 (34.8) |
Characteristic . | n (%) . |
---|---|
Underlying disease | |
Lymphoma | 12 (6.0) |
Acute leukemia | 59 (29.4) |
Chronic leukemia | 95 (47.3) |
Aplastic anemia | 11 (5.5) |
Myelodysplastic syndrome | 19 (9.5) |
Miscellaneous | 5 (2.5) |
Source of stem cells | |
Bone marrow | 169 (84.1) |
Peripheral mobilized stem cell | 32 (15.9) |
Age, y; median (range) | 40 (2-66) |
Sex | |
Male | 116 (57.7) |
Female | 85 (42.3) |
Transplant type | |
Matched related | 133 (66.2) |
Mismatched/unrelated | 68 (33.8) |
Total body irradiation conditioning | 105 (52.2) |
Received ganciclovir | |
Yes | 154 (76.6) |
No | 46 (22.9) |
Data not available | 1 (0.5) |
Steroid use* | |
None | 77 (39.1) |
Between 0 and 1 mg/kg/d | 62 (31.5) |
At least 2 mg/kg/d | 58 (29.4) |
GVHD | |
Grade 0 to 1 | 62 (30.9) |
Grade II | 103 (51.2) |
At least grade III | 36 (17.9) |
Donor CMV serology | |
Positive | 131 (65.2) |
Negative | 70 (34.8) |
An accurate assessment of steroid dose could not be performed for 4 patients.